Smith, Moore & Co. Eq Rx, Inc. Transaction History
Smith, Moore & Co.
- $1.03 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding EQRX
# of Institutions
7Shares Held
67.8MCall Options Held
0Put Options Held
0-
Ah Equity Partners Bio Iii, L.L.C. Menlo Park, CA19.2MShares$0100.0% of portfolio
-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA17.4MShares$060.15% of portfolio
-
Arboretum Ventures, Inc.13.9MShares$063.96% of portfolio
-
Ah Equity Partners Lsv I, L.L.C. Menlo Park, CA11.4MShares$08.42% of portfolio
-
Ah Equity Partners Lsv Ii, L.L.C. Menlo Park, CA5MShares$011.61% of portfolio
About EQRx, Inc.
- Ticker EQRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 448,140,992
- Description
- EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...